This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/iuphar/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/guide-to-pharmacology/
n13http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/wikipedia/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/bindingdb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00391/identifier/drugbank/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00391
rdf:type
n3:Drug
n3:description
A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
n3:group
approved
n3:halfLife
6 to 8 hours
n3:indication
Sulpiride is indicated for the treatment of schizophrenia.
owl:sameAs
n7:DB00391 n20:DB00391
dcterms:title
Sulpiride
adms:identifier
n11:PA164745485 n14:Sulpiride n15:5162 n16:DB00391 n17:11638 n18:D01226 n19:5355 n21:958 n22:958 n23:46504855
n3:mechanismOfAction
In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.
n3:synonym
Sulpirida Levosulpiride Sulpirid 5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide Levosulpiridum Sulpiridum N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide Sulpyrid (+-)-Sulpiride Levosulpirida
n3:toxicity
Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.
n12:hasConcept
n13:M0020813
n3:IUPAC-Name
n4:271B411D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4123-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4122-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B411F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4120-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4121-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4133-363D-11E5-9242-09173F13E4C5 n4:271B411B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4135-363D-11E5-9242-09173F13E4C5 n4:271B411C-363D-11E5-9242-09173F13E4C5 n4:271B4119-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B411A-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4137-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:N05AL01
n3:H-Bond-Acceptor-Count
n4:271B4129-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B412A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4124-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4125-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4127-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4126-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4128-363D-11E5-9242-09173F13E4C5
n3:absorption
Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B4136-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
15676-16-1
n3:category
n3:Bioavailability
n4:271B412F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4131-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4132-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4134-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B412E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B412D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4130-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B411E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B412B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B412C-363D-11E5-9242-09173F13E4C5